The short answer
Mass spectrometry compares an observed mass against an expected one, so any impurity with the same molecular formula is invisible to it. That includes isoaspartyl rearrangements, D-amino acid epimers and misfolded disulfide isomers, all real and all identical in mass.
Key facts
- What MS establishes
- Molecular mass, therefore formula
- Invisible: isoaspartate
- Bond moved, same atoms
- Invisible: D-epimers
- Mirror image, same atoms
- Invisible: disulfide isomers
- Wrong pairing, same atoms
- Common to all three
- Identical molecular formula
- What does detect them
- Chromatography, activity, chiral methods
What mass spectrometry is actually doing
Measuring mass-to-charge ratio, from which molecular mass and therefore molecular formula follow. It is an excellent identity check and a poor structural one, because a formula does not specify an arrangement. Any error that rearranges atoms without adding or removing them produces an identical spectrum.
Isoaspartyl rearrangement
Aspartimide formation can reopen to place the chain through the aspartate side-chain carboxyl rather than the backbone one. Same atoms, different connectivity, identical mass. It is the most common such error in aspartate-containing peptides and it is sequence-dependent, so susceptibility can be predicted from the sequence even though the product cannot be seen by mass.
Research material referenced
BPC-157 5mg, third-party HPLC tested
D-amino acid epimers
Racemisation during synthesis converts an L residue to its D form. A mirror image has identical mass and identical formula. No analytical mass difference exists to detect. This cuts both ways: MT-2 contains a deliberate D-phenylalanine, and mass spectrometry equally cannot confirm that it is present as specified. A sequence written without stereochemistry is not a complete specification.
Misfolded disulfide isomers
A protein with three disulfide bonds has six cysteines that can pair fifteen ways, of which one is correct. Every incorrect pairing has the same mass as the right one. IGF-1 LR3 is exactly this case, and it is why a certificate reporting mass and purity for a recombinant disulfide-containing protein has not addressed whether the molecule is folded correctly.
What does catch them
Chromatography, sometimes. These variants can differ in retention even at identical mass, which is why an unexplained shoulder on a peak deserves attention. Chiral analysis for stereochemistry. Activity assays for conformation, since a misfolded protein does not work. Each requires a method beyond the two that certificates usually carry.
The general point worth carrying
Mass confirms a molecule has the expected composition. It does not confirm the atoms are arranged as intended. Most peptide documentation answers composition twice (purity by HPLC and mass by MS) and never addresses arrangement at all, which is the gap these three impurity classes occupy.
Quick reference
| Impurity | What changed | Detected by |
|---|---|---|
| Isoaspartyl peptide | Bond position | Chromatography, specific assays |
| D-amino acid epimer | Stereochemistry | Chiral analysis |
| Disulfide isomer | Cysteine pairing | Activity, conformational methods |
| Deletion sequence | A residue missing | Mass spectrometry (this one is visible) |
Frequently asked questions
Why can't mass spectrometry detect these?
It measures mass, from which formula follows. All three have the identical formula. Atoms were rearranged, not added or removed.
Does a clean mass spectrum mean a peptide is correct?
It means the composition is as expected. It says nothing about whether the atoms are arranged as intended.
What detects them instead?
Chromatography sometimes, chiral analysis for stereochemistry, and activity assays for conformation.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedRuczyński J et al., Aspartimide formation in Fmoc-based SPPS. J Pept Sci 2008 (PMID 17975850)pubmed.ncbi.nlm.nih.gov
- PubMedCao L et al., Aspartimide formation and hydrolysis kinetics. Biochemistry 2023 (PMID 36701287)pubmed.ncbi.nlm.nih.gov
- PubMedMilner SJ et al., B-domain mutations influence oxidative folding of IGF-I. Biochem J 1995 (PMID 8948444)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Peptide Reference articles
- Endotoxin: The Contaminant That Is Not a ProteinEndotoxin provokes strong biological responses at tiny concentrations and appears in no purity figure. It can also hide from the assay meant to find it.
- Peptides and Muscle Growth: Claims Against EvidenceThe compounds marketed for muscle growth work by different mechanisms, and most evidence measures hormones rather than muscle. What has actually been shown.
- Are Peptides Safe? It Depends Entirely on Which OneInsulin is a peptide. So is a compound with no human data at all. Safety is a property of the specific molecule and the specific material, not of the category.
- Are Peptides Steroids?No. Peptides are amino acid chains; steroids are built on a four-ring carbon skeleton. Different structures, different receptors, different regulation.
- Are Peptides Legal in the UK?Peptides are not one legal category. Most are not controlled drugs, most are not licensed medicines, and supply for human use is where the law actually bites.